Next Article in Journal
Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes
Previous Article in Journal
Human Red Blood Cells as Oxygen Carriers to Improve Ex-Situ Liver Perfusion in a Rat Model
 
 
Article

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study

1
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
2
Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea
3
Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea
4
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
These two authors contributed equally to this study.
J. Clin. Med. 2019, 8(11), 1920; https://doi.org/10.3390/jcm8111920
Received: 15 September 2019 / Revised: 29 October 2019 / Accepted: 7 November 2019 / Published: 8 November 2019
(This article belongs to the Section Oncology)
Background: Olaparib maintenance therapy has shown efficacy and tolerability in patients with platinum-sensitive, high-grade serous recurrent ovarian cancer (HSROC) with BRCA1/2 mutation (BRCAm). Our aim was to present real-world experience with olaparib in Korea. Method: We included HSROC patients with BRCAm treated with olaparib maintenance at four institutions in Korea between 2016 and 2018. Medical records were reviewed for clinico-pathologic characteristics, objective response, survival outcomes, and safety. Results: One hundred HSROC patients with BRCAm were included. BRCA1 mutation was present in 71 patients (71.0%), and BRCA2 mutation was present in 23 patients (23.0%). In terms of the best objective response with olaparib maintenance in 53 patients with partial remission from most recent chemotherapy, complete remission occurred in 12 (22.6%) and partial remission in four (7.5%), while 33 patients (62.3%) had stable disease. The 24 month progression-free survival was 42.4%, and 24 month overall survival was 82.1%. Grade 3 or more adverse events were as follows: anemia in 14 patients (14.0%), neutropenia in seven patients (7.0%), thrombocytopenia in two patients (2.0%), oral mucositis in one patient (1.0%), and soft tissue infection in one patient (1.0%). Conclusions: The safety and effectiveness of olaparib maintenance treatment in a real-world study were consistent with those reported in previous clinical trials. View Full-Text
Keywords: olaparib; recurrent ovarian epithelial carcinoma; maintenance therapy; treatment efficacy; adverse effects olaparib; recurrent ovarian epithelial carcinoma; maintenance therapy; treatment efficacy; adverse effects
Show Figures

Figure 1

MDPI and ACS Style

Paik, E.S.; Lee, Y.J.; Lee, J.-Y.; Shin, W.; Park, S.-Y.; Kim, S.I.; Kim, J.-W.; Choi, C.H.; Kim, B.-G. Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. J. Clin. Med. 2019, 8, 1920. https://doi.org/10.3390/jcm8111920

AMA Style

Paik ES, Lee YJ, Lee J-Y, Shin W, Park S-Y, Kim SI, Kim J-W, Choi CH, Kim B-G. Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. Journal of Clinical Medicine. 2019; 8(11):1920. https://doi.org/10.3390/jcm8111920

Chicago/Turabian Style

Paik, E Sun, Yong Jae Lee, Jung-Yun Lee, Wonkyo Shin, Sang-Yoon Park, Se Ik Kim, Jae-Weon Kim, Chel Hun Choi, and Byoung-Gie Kim. 2019. "Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study" Journal of Clinical Medicine 8, no. 11: 1920. https://doi.org/10.3390/jcm8111920

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop